Answers are grounded in this paper and cite their sources.
Emerging evidence indicates a high prevalence of undetected micronutrient deficiencies in apparently healthy adults (1) . Suboptimal and deficient levels of key nutrients can have a substantial impact on quality of life and chronic disease risk. Therefore, it is crucial to identify easily accessible interventions to help correct such micronutrient deficiencies. Previously, we showed significant improvements in a number of key nutrient biomarkers in a pilot trial of the multivitamin supplement Vitals+ (2) . The aim of the present study was to investigate the efficacy of Vitals+ supplementation on blood-based biomarkers of key nutrients in healthy adults in a double-blind, placebo-controlled trial. A multicentre, randomised, double-blind, placebo-controlled trial was conducted in 35 healthy adults (66%female, aged 29±4 yrs), across recruitment sites in Manchester and London. Participants were recruited through The Functional Gut Clinic’s research participant database and through advertisement on social media. Participants were randomised in a 2:1 ratio to receive either the multivitamin Vitals+ (Heights,London) or a matched placebo control for a duration of 12 weeks. A fasted blood sample was drawn pre and post intervention for nutrient biomarker assessment. Folate was measured in red blood cells (RBCF), holotranscobalamin (HoloTC) in serum was utilised for B12 and B6 (Pyridoxal-5’-Phosphate; PLP) and homocysteine were measured in plasma. Riboflavin status was assessed using the functional Erythrocyte Glutathione Reductase activation coefficient (EGRac) assay. Clinical blood safety parameters, including renal, hepatic and haematology bloods and adverse event monitoring were used to assess safety profile. At baseline, 40% of participants presented with folate deficiency (RBCF <340nmol/L) and 34% with B12 deficiency (HoloTC <70 pmol/L). 83% had suboptimal or deficient riboflavin status (EGRac ≥1.27) and 51% with elevated homocysteine levels (plasma homocysteine>10 μmol/L). There were no cases of Vitamin B6 deficiency. Two way (TreatmentXTime) mixed model ANOVA reported significant (p <0.05) time by treatment group effects with significant increases in the Vitals+ group from baseline for folate (82% increase;p <0.001), Vitamin B12 (25% increase;p <0.01), Vitamin B6 (115% increase;p <0.001), riboflavin (17% increase;p <0.05) and a significant decrease in homocysteine concentrations (33% reduction;p <0.01). Evaluation of the safety profile indicated that there were no clinically significant differences in the blood safety parameters or adverse events between Vitals+ and the placebo group. This study reports a high level of micronutrient deficiencies in an apparently healthy population of UK adults. These findings corroborate previous studies reporting a high prevalence of folate (3) , Vitamin B12 (4) and riboflavin (5) deficiencies across UK populations. However, Vitals+ significantly increased biomarker levels of these key nutrients including folate, Vitamin B12, riboflavin and Vitamin B6 whilst also reducing total homocysteine concentrations. These findings indicate this multivitamin offers an easily accessible intervention to help correct hidden micronutrient deficiencies and lower homocysteine concentrations in healthy adults.
No takes yet. Share an insight, caveat, or question.
Jarrett et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: